<DOC>
	<DOCNO>NCT00058539</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Omnitarg ( Pertuzumab ) cancerous lesion men castration-resistant ( hormone-refractory ) prostate cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Pertuzumab Treat Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent Age &gt; = 18 year old Histologically document adenocarcinoma prostate , clinically refractory resistant hormone therapy , assess progression follow least one hormonal therapy ( orchiectomy luteinizing hormonereleasing hormone [ LHRH ] agonist ) . Subjects must document progression follow hormonal therapy withdrawal &gt; = 4 week duration ; nilutamide bicalutamide require 6 week withdrawal . Progression disease one prior chemotherapy regimen ( must taxanebased ) CRPC . Progression define least one following : A minimum three consecutive serum PSA measurement obtain &gt; = 14 day apart within 3 month , progressively increase value two consecutive measurement . The late value must obtain within screening period must &gt; = 5 ng/mL ; progression measurable disease , defined RECIST ; progression bone disease , define appearance one new bone lesion Orchiectomy , castrate level testosterone maintain LHRH agonist &lt; 70 ng/mL Life expectancy &gt; = 12 week ECOG performance status 0 1 Granulocyte count &gt; = 1500/mL , platelet count &gt; = 75,000/mL hemoglobin &gt; = 9 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbopoeitin [ Aranesp ] permit ) Serum bilirubin less equal upper limit normal ( ULN ) , unless due Gilbert 's disease , alkaline phosphatase , AST , ALT &lt; = 2.5 x ULN ( ALT , AST , alkaline phosphatase &lt; = 5 x ULN subject liver metastasis ; alkaline phosphatase upper limit subject bone metastasis ) Serum creatinine &lt; = 1.5 x ULN International normalize ratio ( INR ) &lt; 1.5 activate partial thromboplastin time ( aPTT ) &lt; 1.5 x ULN ( except subject receive warfarin ) Willing complete serial PROSQOLI/PPI evaluation serial diary analgesic use ( necessary ) Prior chemotherapy , radiotherapy , therapeutic radionucleotide immunotherapy within 4 week Day 1 ( day first rhuMAb 2C4 dose ) . Flutamide therapy , second line hormonal therapy withdraw &gt; = 4 week prior Day 1 . Bicalutamide nilutamide therapy withdrawn &gt; = 6 week prior start study medication . Prior treatment HER2 pathway inhibitor ( e.g. , Herceptin [ Trastuzumab ] , Iressa [ gefitinib ] , Tarceva [ erlotinib hydrochloride ] , C225 , CI1033 , TAK165 ) Treatment experimental anticancer agent within 4 week prior Day 1 Prior history clinical evidence central nervous system brain metastasis Ejection fraction , determine ECHO , &lt; 50 % Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Prior exposure &gt; 360 mg/m2 doxorubicin , &gt; 120 mg/m2 mitoxantrone , &gt; 90 mg/m2 idarubicin Ongoing corticosteroid treatment , except subject stable dos &lt; 20 mg prednisone daily ( equivalent ) , take corticosteroid reason unrelated prostate cancer History malignancy within 5 year prior Day 1 , except adequately treat basal squamous cell skin cancer History serious systemic disease , include active infection , uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg two consecutive occasion ) , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation , paroxysmal supraventricular tachycardia , control hypertension eligible ) Ongoing liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Major surgery significant traumatic injury within 3 week prior Day 1 Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>